Provided by Tiger Trade Technology Pte. Ltd.

Onconetix Inc.

0.6505
-0.0165-2.47%
Post-market: 0.6400-0.0105-1.61%19:38 EDT
Volume:225.62K
Turnover:145.26K
Market Cap:2.57M
PE:-0.24
High:0.6660
Open:0.6510
Low:0.6207
Close:0.6670
52wk High:209.50
52wk Low:0.6207
Shares:3.95M
Float Shares:3.71M
Volume Ratio:0.67
T/O Rate:6.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.6880
EPS(LYR):-828.1488
ROE:-105.23%
ROA:-27.03%
PB:0.19
PE(LYR):0.00

Loading ...

Company Profile

Company Name:
Onconetix Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
- -
Office Location:
201 East Fifth Street,Suite 1900,Cincinnati,Ohio,United States
Zip Code:
45202
Fax:
- -
Introduction:
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Directors

Name
Position
Andrew Oakley
Non Executive Chairman
Sarah Romano
Director
Thomas Meier
Director
Timothy Ramdeen
Director

Shareholders

Name
Position
Karina Fedasz
Interim Chief Executive Officer and Interim Chief Financial Officer